Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Frequently asked questions
What sector does Immunome, Inc (IMNM) operate in?
Immunome, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Immunome, Inc (IMNM) current stock price?
As of the latest data, Immunome, Inc stock price is $17.89, with a previous close of $17.99. Immunome, Inc lost -$0.10 in the last trading session, representing a -0.56% loss.
What is Immunome, Inc (IMNM) current market capitalization?
Immunome, Inc market cap is approximately 2.03 billion.
What is Immunome, Inc (IMNM) Earnings Per Share (EPS)?
The trailing EPS is -$2.58, and the forward EPS is -$2.48.
What is Immunome, Inc (IMNM) EBITDA?
Immunome, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -72.17 million.
Does Immunome, Inc (IMNM) pay dividends?
No. Immunome, Inc does not pay a dividend.
When is Immunome, Inc (IMNM) next earnings report?
Immunome, Inc is expected to release its next earnings report on September 30, 2026.
What is Immunome, Inc (IMNM) beta (volatility) score?
Immunome, Inc has a beta of 2.133, indicating very high volatility compared to the market.
